Skip to Main Content

A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumors


Phase I

Phase I

What is the purpose of this trial?

The primary objectives of this study are to identify the recommended dose for expansion (RDE) (and recommended schedule) and/or maximum tolerated dose (MTD), and to characterize the safety and the tolerability of ADCT-901.

  • Trial with
    ADC Therapeutics SA
  • Start Date
  • End Date

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email or call 877.978.8343

  • Last Updated
  • Study HIC